Clinical Trial Update: A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a two-dose Ebola vaccine regimen (Ad26.ZEBOV prime followed by MVA-BN-Filo boost) in healthy pregnant women has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ad26.ZEBOV
• MVA-BN-Filo

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Healthy | Phase 3 | Status: COMPLETED